FcγRIIIa-dependent IFN-γ release in whole blood assay is predictive of therapeutic IgG1 antibodies safety

Immunomodulatory monoclonal IgG1 antibodies developed for cancer and autoimmune disease have an inherent risk of systemic release of pro-inflammatory cytokines. In vitro cytokine release assays are currently used to predict cytokine release syndrome (CRS) risk, but the validation of these preclinica...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:MAbs
Hauptverfasser: Alakhras, Nada S., Qiu, Jiabin, Rocha, Guilherme V., Witcher, Derrick R., Koester, Anja, You, Jinsam, Schaer, David A., Holmgaard, Rikke B., Driscoll, Kyla, Willy, Jeffrey A., Malherbe, Laurent P.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Taylor & Francis 2018
Schlagworte:
Report
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6152447/
https://ncbi.nlm.nih.gov/pubmed/29953319
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2018.1474996
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge